## NAEPP EPR-3 Classification of Asthma Severity & Control in Children 0-4 Years of Age

Classifying Asthma Severity & Initiating Treatment

Components of Severity		Classification of Asthma Severity				
		Intermittent	Persistent			
			Mild	Moderate	Severe	
Impairment	Symptoms	≤ 2 days/week	> 2 days/week but not daily	Daily	Throughout the day	
	Nighttime Awakenings	0	1-2x/month	3-4x/month	> 1x/week	
	SABA Use (other than for EIB)	≤ 2 days/week	> 2 days/week but not daily	Daily	Several times/day	
	Interference with Normal Activity	None	Minor limitation	Some limitation	Extremely limited	
Risk	Exacerbation requiring OSC	0-1/year	≥ 2 exacerbations in 6 months requiring OSC, or ≥ 4 wheezing episodes/1 year lasting > 1 day AND risk factors for persistent asthma			
		Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over time. Exacerbations of any severity may occur in patients in any severity category.				
Recommended Step for Initiating Therapy The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs.		Step 1	Step 2	Step 3 and Consider OSC	Step 3 and Consider OSC	
Classifying Severity After Asthma Becomes Well-Controlled by Lowest Level of Treatment Required to Maintain Control						
Classification of Asthma Severity						
Lowest level of treatment		Intermittent	Persistent			
			Mil.J	Madavata	Courses	

KEY: SABA-short-acting beta, agonist; ICS-inhaled corticosteroids; OSC-oral systemic corticosteroids; EIB-exercise induced bronchospasm

Step 1

NOTES:

Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous 2-4 weeks. Symptom assessment for longer periods should reflect a global assessment such as inquiring whether the patient's asthma is better or worse since the last visit. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. For treatment purposes, patients who had > 2

Step 2

Mild

Moderate

Step 3 or 4

Severe

Step 5 or 6

exacerbations requiring oral systemic corticosteroids in the past 6 months, or ≥ 4 wheezing episodes in the past year, and who have risk factors for persistent asthma may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.

	Classifying Asthma Control	& Adjusting Treatment
--	----------------------------	-----------------------

required to maintain control

Components of Control		Classification of Control			
		Well Controlled	Not Well-Controlled	Very Poorly Controlled	
Impairment	Symptoms	≤ 2 days/week	> 2 days/week	Throughout the day	
	Nighttime Awakenings	≤ 1x/month	> 1x/month	> 1x week	
	Interference with Normal Activity	None	Some limitation	Extremely limited	
	SABA Use (other than for EIB)	≤ 2 days/week	> 2 days/week	Several times/day	
Risk	Exacerbation requiring OSC	0-1 year	2-3 year	> 3/year	
		Consider severity and interval since last exacerbation.			
	Treatment-related adverse side effects	Medication side effects vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.			
Recommended Action for Treatment The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs.		<ul> <li>Maintain current treatment.</li> <li>Regular follow-up every 1-6 months.</li> <li>Consider step down if well controlled for at least 3 months.</li> </ul>	<ul> <li>Step up (1 step) AND</li> <li>Reevaluate in 2-6 weeks.</li> <li>If no clear benefit in 4-6 weeks, consider alternative diagnosis or adjusting therapy.</li> <li>For side effects, consider alternative treatment options.</li> </ul>	<ul> <li>Consider short course of OSC.</li> <li>Step up (1-2 steps), AND</li> <li>Reevaluate in 2 weeks.</li> <li>If no clear benefit in 4-6 weeks, consider alternative diagnosis or adjusting therapy.</li> <li>For side effects, consider alternative treatment options.</li> </ul>	

KEY: SABA-short-acting beta,-agonist; ICS-inhaled corticosteroids; OSC-oral systemic corticosteroids; EIB-exercise induced bronchospasm

NOTES:

The level of control is based on the most severe risk category. Assess impairment domain by caregiver's recall of previous 2-4 weeks. Symptom assessment for longer periods should reflect a global assessment such as inquiring whether the patient's asthma is better or worse since the last visit.

At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (e.g., requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had ≥ 2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.

Before step up in therapy:

Review adherence to medication, inhaler technique, environmental control, and comorbid conditions.

If alternative treatment option was used in a step, discontinue it and use preferred treatment for that step.

Produced by the California Asthma Public Health Initiative (CAPHI). Based on NAEPP EPR-3 recommendations for classification of asthma severity and control for children 0-4 years of age. This table was designed to assist the clinician and is not intended to replace the clinician's judgment or establish a protocol for all patients with a particular condition. Revised 02/16/2010